The Editors of HDBuzz cover the CHDI Therapeutics Conference
Posted on March 10, 2022
For the first time in two years, scientists, clinicians, and industry partners convened in Palm Springs, CA for CHDI foundation’s 17th Annual HD Therapeutics Conference….
Read MoreHDBuzz Covers the CHDI Conference
Posted on March 3, 2022
CHDI is a privately funded HD research foundation whose mission is to further development of HD therapies. This week, they’re hosting…
Read MoreRaise Awareness of Rare Disease Day with HDSA February 28th
Posted on February 24, 2022
When you have a rare disease, you face two battles – one being the illness itself, and the other, living…
Read MoreQuick Question: Genetic Testing and Rare Disease
Posted on February 17, 2022
Check out HDSA’s new short video series, “Quick Question,” in which HDSA’s Jennifer Simpson, LCSW (Assistant Director of Youth &…
Read MoreA new mouse model for HD: The scoop from HDBuzz
Posted on February 10, 2022
Researchers at UCLA have developed a new mouse model for HD that more closely resembles human HD than ever before….
Read MoreSplicing Modulators for HD: HDBuzz Covers PTC Therapeutics’ HTT-lowering approach
Posted on February 3, 2022
Huntingtin lowering (HTT-lowering) has been touted as a promising avenue for treatment of HD because it targets the cause of…
Read MoreUpdate from Novartis on Planned Trial of Branaplam for Huntington’s Disease
Posted on January 27, 2022
Novartis is developing an experimental HD therapy called branaplam which has the potential to lower huntingtin when taken by mouth. Branaplam…
Read MoreRoche to continue development of tominersen: Community Presentation TODAY
Posted on January 20, 2022
In a community letter released January 18th, Roche announced plans to continue developing the huntingtin-lowering drug tominersen. After analyzing data collected in the Phase III GENERATION HD-1 trial that halted dosing in…
Read MoreResearch Webinar: Roche Joins HDSA to Discuss Latest Data from GENERATION HD-1
Posted on January 13, 2022
One week from today, HDSA will be joined by members of the Roche team at 3:00 PM EST on January 20th for…
Read MoreUpcoming Webinar: New Key Findings from the GENERATION HD-1 Study
Posted on January 6, 2022
Join HDSA at 3:00 PM EST on January 20th for an update from Roche on new findings from the data collected in the GENERATION HD-1 study. This…
Read MoreHappy Holidays from HDSA
Posted on December 23, 2021
Through all the challenges 2021 had in store, the resilience of the HD community has continued to inspire HDSA in our…
Read MoreuniQure opens new study sites and changes inclusion criteria for AMT-130 trial
Posted on December 16, 2021
In a press release published this morning, uniQure announced that AMT-130, an investigational gene therapy for treatment of Huntington’s disease,…
Read MoreA new Biomarker for HD: HDBuzz on radiolabels for mHTT
Posted on December 9, 2021
A research team led by Dr. Celia Dominguez at CHDI has identified a new method to track the presence of…
Read MoreMark Your Calendars: “Ask the Scientists … Anything” HDSA Research Webinar
Posted on December 2, 2021
As November chill slowly turns to December cold, mark your calendars for HDSA’s final research webinar of the year on Tuesday, December 7th. Three editors…
Read MoreNow Accepting Applications for 2022 Berman-Topper and Donald A. King Research Fellowships
Posted on November 18, 2021
Earlier this week on November 16, HDSA launched applications for the 2022 cycles of its prestigious Berman-Topper Family HD Career…
Read MoreWebinar TODAY! Take Action and Support the HD Parity Act
Posted on November 11, 2021
We talk a lot about what we’re hopeful for tomorrow here in the research world, and it’s equally important to…
Read MoreResearch Wrap-Up: HDBuzz Covers EHDN’s Annual Research Conference
Posted on November 4, 2021
In September, the European Huntington’s Disease Network brought together scientists and stakeholders from around the world for updates from experts in…
Read MoreHDSA Research Webinar 11/3/21: Register TODAY!
Posted on October 28, 2021
Dr. Jane Paulsen will join HDSA next week to discuss a new observational trial, PREVENT-HD, Preparing for the Prevention of Huntington’s…
Read MorePrilenia Therapeutics and HSG announce completion of participant enrollment in PROOF-HD
Posted on October 21, 2021
In a recent press release, Prilenia Therapeutics and the Huntington’s Study Group (HSG) announced the completion of participant enrollment in PROOF-HD,…
Read MoreHDSA Awards Five Huntington’s Disease Human Biology Project Research Grants
Posted on October 14, 2021
After thoughtful deliberation by its Scientific Advisory Board, HDSA will award five the Huntington’s Disease Human Biology Project research grants to Joan O’Keefe,…
Read More